Suchergebnisse - "Lordick, F"

PubPharm (15)

1

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial

enthalten in: ESMO open | 2023

von Stocker, G. | Lorenzen, S. | Ettrich, T. | +16

2

Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Hacker, U. | Hasenclever, D. | Baber, R. | +6

CommentIn: Ann Oncol. 2022 Jul;33(7):669-671. - PMID 35430371

3

FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Sahin, U. | Türeci, �. | Manikhas, G. | +15

CommentIn: Ann Oncol. 2021 May;32(5):584-586. - PMID 33677015

4

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer : a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Moehler, M. | Maderer, A. | Thuss-Patience, P. | +17

CommentIn: Ann Oncol. 2020 Feb;31(2):161-162. - PMID 31959330

5

Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Dietz, A. | Wichmann, G. | Kuhnt, T. | +41

6

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

enthalten in: Bone marrow transplantation | 2017

von Huhn, S. | Weinhold, N. | Nickel, J. | +24

7

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Folprecht, G. | Gruenberger, T. | Bechstein, W. | +14

8

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Peeters, M. | Price, T. | Cervantes, A. | +14

ErratumIn: Ann Oncol. 2014 Mar;25(3):757

9

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND) : a randomised, open-label phase 3 trial

enthalten in: The Lancet. Oncology | 2013

von Lordick, F. | Kang, Y. | Chung, H. | +114

CommentIn: Lancet Oncol. 2013 May;14(6):440-2. - PMID 23594785

10

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial

enthalten in: JAMA | 2012

von Neoptolemos, J. | Moore, M. | Cox, T. | +122

ErratumIn: JAMA. 2012 Nov 14;308(18):1861